View More Posts


The article starts 'What if we have got it wrong on Alzheimer's? Science is about getting it wrong, until you get it right. What if we're refusing to admit we're wrong about a horrifying disease?'

This article shows that people are starting to question the amyloid hypothesis which only proves to strengthen the novel approach that Neuro-Bio is taking to tackle Alzheimer's Disease. 

Click HERE to read the whole article on why a new approach to Alzheimer's Disease is necessary. 

Read More

During the second half on March 2018, Professor Susan Greenfield will be visiting Melbourne, sponsored by the University of Melbourne. Whilst in Australia she will meet with our current Australian investors and update them on the rapid pace of progress of Neuro-Bio research. Peter Yates, Deputy Chairman of The Myer Family Investments Ltd, who heads the syndicate of Australian angels and is a long-standing supporter of the Neuro-Bio approach, is also kindly hosting various events where Susan will be presenting to a wider audience.

Read More

Neuro-Bio recently featured on Oxfordshire's local TV channel. Follow this link to see an interview with Baroness Professor Susan Greenfield on Alzheimer's Disease, Series B funding and our new premises.


Neuro-Bio Secure Millions in Funding for Alzheimer's Research

Published on Feb 6, 2018

Neuro-Bio is an Oxford University spin-out that's pioneering an alternative approach to talking neurodegenerative diseases such as Alzheimer's. Based at the Culham Science Centre the bioteach firm has won millions in funding from a US Company. Our Reporter Alex Meakin has more.

That's Oxfordshire

Find out more about the work of Baroness Susan Greenfield on her personal website. You can also connect with Susan Greenfield on LinkedIn. Watch this video to learn more about her research.

Read More

ABOUT Neuro Bio

Neuro-Bio is a privately-owned biotech out of Oxford University with a therapeutic focus on neurodegenerative disease. The company has discovered a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE. T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of neurodegeneration. This new distinct mechanism is being exploited by Neuro-Bio to discover oral drugs to treat Alzheimer's disease. T14 can also be measured in blood and Neuro-Bio is developing this biomarker as a companion diagnostic.

Dr Richard Mohs


"I compliment you on development of this novel and innovative approach to AD…the idea of linking known facts about selective neuronal vulnerability with both novel biomarkers and novel therapeutics is really quite exciting and is something completely absent from current approaches focusing heavily on amyloid-beta and tau."

Chief Scientific Officer, Global Alzheimer’s Platform, Nov 2017


Baroness Professor Susan Greenfield, CBE

CEO and Founder

Baroness Greenfield is a British scientist, writer and broadcaster. Susan has published over 200 papers in peer-reviewed journals over the course of her distinguished career. She holds 32 honorary degrees from UK and foreign universities, and has received numerous honours including the Australian Medical Research Society Medal and Legion d’Honneur from the French Government. Susan also has an Honorary Fellowship from the Royal College of Physicians and is a member of the Fellowship of the Royal Society of Edinburgh.

David Fuente

Investor Director

David is an experienced manager and director having been Chairman and CEO of a number of companies across a wide variety of sectors.
He has a Master’s degree from Purdue University.

Dominique Kleyn

Commercial Director

Dominique has experience sitting on a number of Boards, as a non-executive director, across the Healthcare sector. Her skills lie within business development and marketing.
Dominique has an MBA from Imperial University.